Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy by Hamid, Agus Rizal A. H. et al.
RESEARCH ARTICLE Open Access
Early upregulation of AR and
steroidogenesis enzyme expression after 3
months of androgen-deprivation therapy
Agus Rizal A. H. Hamid1* , Harun W. Kusuma Putra1, Ningrum Paramita Sari2, Putri Diana1, Saras Serani Sesari1,
Eka Novita3, Fajar Lamhot Gultom3, Meilania Saraswati3, Budiana Tanurahardja3, Asmarinah2, Rainy Umbas1 and
Chaidir A. Mochtar1
Abstract
Background: Androgen deprivation therapy (ADT) is a standard treatment for advanced prostate cancer (PCa).
However, PCa recurrence and progression rates during ADT are high. Until now, there has been no evidence
regarding when progression begins. This study evaluated the gene expression of intraprostatic androgen receptor
(AR) and steroidogenic enzymes in the early stages of ADT.
Methods: Prostate tissue samples were taken from PCa patients with urinary retention who received ADT (ADT-PCa;
n = 10) and were further subgrouped into ADT ≤12 months (n = 4) and ADT > 12 months (n = 6). The ADT-PCa
tissues were then compared with BPH (n = 12) and primary (no treatment) PCa tissues (n = 16). mRNA for gene
expression analysis of AR and steroidogenic enzymes was extracted from formalin-fixed paraffin embedded (FFPE)
tissues and analyzed by real-time PCR. Protein expression was evaluated by immunohistochemistry with specific
antibodies.
Results: AR gene expression was higher in the ADT-PCa group than in the BPH or primary PCa group. Both the
ADT ≤12 and > 12 months subgroups had significantly higher relative gene expression levels of AR (p < 0.01 and
0.03, respectively) than the primary PCa group. In the ADT-PCa group, AR protein expression showed an increasing
trend in the ADT ≤12 months subgroup and was significantly elevated in the ADT > 12 months subgroup
compared with the PCa group (100%; p < 0.01). Half (50%) of the patients in the ADT ≤12 months subgroup were
found to have upregulation of AR, and one showed upregulation beginning at 3 months of ADT. A trend toward
elevated relative gene expression of SRD5A3 was also apparent in the ADT groups.
Conclusion: AR and steroidogenic enzymes are upregulated in ADT-PCa patients as early as 3 months, without PSA
elevation. Steroidogenic enzymes, particularly SRD5A3, were also upregulated before PSA rose.
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Background
Over the years, there have been notable improve-
ments in the development of prostate cancer (PCa)
treatment, resulting in better prognoses [1]. However,
40% of patients with early PCa are still at risk of dis-
ease progression to a more advanced stage [1] and
thus need androgen deprivation therapy (ADT), the
current standard palliative treatment [2]. Although
ADT may prolong overall survival [3], prolong the
occurence of metastasis [4], and decrease PSA levels
[5], these effects are only temporary. The disease
often progresses further after 2–3 years of treatment
[6]. This form of late-stage PCa is called castration-
resistant prostate cancer (CRPC), as PCa cells have
evolved and become capable of both hormone-
dependent and hormone-independent cell proliferation
and survival [7].
The existence of CRPC has motivated an increased
focus on the disease. The androgen receptor (AR) signal-
ing pathway is an important mechanism of PCa and
plays a key role in PCa progression [8–10]. The known
mechanisms of resistance include AR overexpression,
AR gene amplification, AR hypersensitivity, AR muta-
tions, AR variants (ARVs), androgen-independent AR
activation, and intratumoral and alternative androgen
production [8–10]. Furthermore, data have suggested
that the increased level of intraprostatic AR can lead to
disease progression [10]. Other downstream steroido-
genic enzymes within the AR signaling pathway, 5α-
reductase and AKR1C3, have also become targets of
interest [7–12]. These enzymes are responsible for the
conversion of androgens into dihydrotestosterone
(DHT), which is needed by PCa cells [11]. Currently,
there are three identified isozymes of SRD5A encoded
by 3 different genes: SRD5A1, SRD5A2, and SRD5A3
[11]. AKR1C3, SRD5A1 and SRDA2 have been exten-
sively studied [7–12], and marked changes in their levels
were reported to occur during the course of PCa devel-
opment and progression [7–12]. SRD5A1 and SRD5A3
are associated with androgen response elements (AREs)
that promote the transcription of target genes, leading to
cell homeostasis, angiogenesis, differentiation, and apop-
tosis [13]. It is also believed that the two isozymes play
important roles in androgen production in prostate cells
[11]. On the other hand, the role of SRD5A3 is still ob-
scure, although associations with DHT production and
AR activation have been suggested [14]. Based on these
findings, AR, AKR1C3, and 5α-reductase are indicative
of PCa progression, as differences in their levels between
malignant and nonmalignant cells have been docu-
mented. However, changes in the levels of these genes
following ADT treatment have never been reported, al-
though they have been associated with further disease
progression and recurrence.
Currently, no study has reported the start of disease
progression after ADT. This study hypothesized that
progression of the disease would likely occur within a
short time interval after commencement of ADT. There-
fore, this study evaluated the early effects of ADT by in-
vestigating the levels of AR and steroidogenic enzymes
as an indicator of disease progression. To this end, we
compared the levels of these factors within the intrapro-
static cells of benign prostatic hyperplasia (BPH) and




Formalin-fixed paraffin embedded (FFPE) prostate tissue
was obtained from the Department of Pathology Anat-
omy, Cipto Mangunkusumo General Hospital (RSCM).
The study included three groups of patients: 1) the BPH
group (n = 12), 2) the primary PCa group (n = 16, sam-
pled from 2009 to 2015), and 3) the PCa after ADT
(ADT-PCa) group (n = 10). The sample retrieval method
for BPH and primary PCa are through biopsy, TUR-P,
or Radical prostatectomy, while ADT-PCa tissues were
taken primarily from TUR-P. The ADT-PCa group was
categorized as the ADT ≤12 months and ADT > 12
months subgroups based on the duration of ADT. All
use of specimens was in compliance with the guidelines
of the local review board and Ethics Committee 520/
UN2, F1/ETIK/2015, and prostatic tissues were obtained
with patient consent at the time of the procedure.
RNA extraction from FFPE tissue
Paraffinization was performed by prior isolation of the
RNA using a High Pure RNA Paraffin Kit (Roche,
Germany). The sample used was FFPE prostate tissues,
which were cut to a thickness of 5–10 μM from each tis-
sue sample from each group (BPH, primary PCa, and
ADT-PCa). DNA extraction was performed from the
FFPE samples. Total RNA was extracted in 50 μl and
stored in a − 80 °C freezer.
Quantitative real-time PCR
Quantification of gene expression (by qPCR) was per-
formed for AR, AKR1C3, SRD5A1, SRD5A2, and
SRD5A3 using a QuantiTect SYBR Green RT-PCR kit.
The 18S gene was the housekeeping gene used as the in-
ternal control due to its constitutive expression across
tissues and cells. qPCR mix (2x QuantiTect SYBR Green
RT-PCR Mix, Forward Primer, Reverse Primer, free
water nuclease) was used to set up the reactions, and
2 μL of the cDNA sample was used as the template. The
specific primers used in this study are shown in Table 1.
Measurements were performed using the Mx3000P (Agi-
lent) tool with an amplification program. The cycle
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threshold (Ct) was obtained by using MxPro (Agilent)
software. Relative gene expression was measured by
using the Livak method, also known as the delta thresh-
old cycle (ΔΔCt).
Immunohistochemistry
Immunohistochemistry was performed by using the FFPE
preparation. Each sample was cut into 4-μm sections,
warmed at 58 °C, and deparaffinized using xylol I, II, and
III. The specimens were rehydrated in a 100, 96, and 80%
graded ethanol series and were then subjected to heat-
induced epitope retrieval (HIER) at pH 6 in a pressure
boiler at 125 °C and cooled at 90 °C. A dual endogenous en-
zyme block was performed using 0.3% H2O2 and 95% etha-
nol. Staining for analysis of the expression of AR, AKR1C3
and steroidogenic enzymes SRD5A1, SRD5A2, and
SRD5A3 was performed using antibodies obtained from
Sigma Aldrich (St Louis, Missouri) [15]: mouse monoclonal
anti-AR (WH0000367M1) [15, 16], mouse monoclonal
anti-AKR1C3 (A6229) [15, 17], rabbit polyclonal anti-
SRD5A1 (HPA051402) [15], rabbit polyclonal anti-SRD5A2
(SAB2105567) [15], and rabbit polyclonal anti-SRD5A3
(HPA027006) [15, 18]. All of the antibodies were validated,
referenced (Human Protein Atlas project) and peer-
reviewed and are widely used in the immunohistochemistry
research field, as referenced by Sigma Aldrich. Additional
information is provided in Supplementary Table 1.
Tissues were incubated with an HRP-labeled poly-
mer followed by chromogenization in DAB (substrate
DAB: chromogen DAB was 1:20) using the DAKO
autostainer Kit. The specimens were then counter-
stained using hematoxylin and dehydrated (100, 80,
96%), cleared (xylol I, II, III), and mounted onto
slides with coverglass.
Slides were assessed visually by three examiners who
were blinded to the patient groups, and the results were
confirmed by an experienced pathologist. Microscopic
semiquantitative examination was performed on 10 ran-
dom fields per specimen containing a minimum of 500
cells using ImageJ (Research Service Branch, NIH.gov) at
400× magnification. Protein expression was considered
positive if the cells staining was brownish in the cyto-
plasm or if the nuclei had a granular pattern.
H-score calculation to measure protein expression
Positively stained epithelial cells were then quantified
using a semiquantitative scoring method of 0, + 1, + 2,
and + 3 with expression scores for each cell. A score of
+ 1 was defined as low positive, + 2 as moderate positive,
and + 3 as high positive. Quantification of protein ex-
pression was performed by measuring the H-score. The
H-score was measured using the following formula:
1 x%þ 1 cellsð Þ þ 2 x%þ 2 cellsð Þ þ 3 x%þ 3 cellsð Þ½ 
The mean H-score of the BPH group was set as the
cut-off to determine which samples showed upregulated
or downregulated protein expressionand the results were
further analyzed for statistical comparisons. The per-
centage of samples with upregulation is presented
Statistical analysis
Statistical analysis was performed using GraphPad Prism
7 (La Jolla, CA). The Mann-Whitney U test was used to
compare gene expression among the groups as follows:
ADT versus BPH and ADT versus PCa. P < 0.05 was de-
fined as statistically significant. Fisher’s exact test was
used for comparisons of protein expression between spe-




From 2007 to 2015, we were able to evaluate 10 patients
who still had urinary retention after ADT treatment
(ADT-PCa group), and their mean age was 67.27 ± 9.69.
The group was then subdivided into two groups: one re-
ceived ADT for under 12 months (4 samples), with a
median treatment time of 5 (3–9) months, and the other
received ADT for more than 12months (6 samples),
with a median treatment time of 30 (15–70) months.
The initial PSA levels were 93.3 (58.14–784.60) in the
ADT ≤ 12months group and 176.9 (104.23–200.40) in
the ADT > 12months group. The Gleason scores of
most of the patients were high [8–10], and the T-stages
and prostate volumes were comparable between the two
groups. The ADT types used were similar and compar-
able between the two groups: in the ADT ≤ 12months
Table 1 Primers for rtPCR
Gene Forward Reverse
AR CAT TGA GCC AGG TGT AGT GT CCA GTT CAT TGA GGC TAG AGA G
AKR1C3 TGC AGG TTT TTG AGT TCC AGT TGG CTA GCA AAA CTA TCA CGT T
SRD5A1 ACG GGC ATC GGT GCT TAA T CCA ACA GTG GCA TAG GCT TTC
SRD5A2 GGAGTCCTTCAAGGCTACTATCT CACCCAAGCTAAACCGTATGT
SRD5A3 GTC ATC TGC CCA TCA GTA TAA GAA TGA CCA CTC CTG CTT TAT
18 S AAA CGG CTA CCA CAT CCA AG CCT CCA ATG GAT CCT CGT TA
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group, 50% of the patients underwent orchiectomy and
50% received LHRH agonist and antiandrogen, while in
the ADT > 12months group, these proportions were 67
and 33% respectively. We also compared these patients
to the BPH group (12 samples) and primary PCa group
(16 samples). The detailed characteristics of the patients
are presented in Table 2. There was statistically signifi-
cant difference of PSA level between the groups, with
the highest PSA level found in the ADT > 12months
group.
Relative gene expression
AR gene expression was higher in the ADT-PCa group
than in the BPH (median difference of 1.1; p-value 0.05)
and primary PCa (median difference of 1.83; p < 0.01)
groups. Patients with ADT ≤12months had the highest
relative AR gene expression (median 5.14). AKR1C3
showed an increasing trend in the ADT-PCa subgroups
compared with the BPH and primary PCa groups
(Fig. 1).
There were no significant differences in the gene ex-
pression of SRD5A1 or SRD5A2 between the groups.
However, a decreasing trend in SRD5A2 gene expression
was noted (Fig. 1). In contrast, an overall increasing
trend in SRD5A3 expression was observed between the
BPH and ADT-PCa subgroups, with the ADT ≤12
months subgroup having the highest relative SRD5A3
expression (median difference of 9.39 in ADT ≤12
months vs the primary PCa group, p = 0.13; median dif-
ference of 11.3 in the ADT ≤12months group vs the
BPH group, p = 0.02) (Fig. 1).
Protein expression by immunohistochemistry
AR and AKR1C3 expression was found in both the nu-
cleus and cytoplasm, while the protein expression of
SRD5A1, SRD5A2, and SRD5A3 was found predomin-
antly in the cytoplasm (Fig. 2). Upregulation of protein








Duration≤ 12 Months n = 4 Duration > 12 Months n = 6
Age 64.2 ± 8.6 63.4 ± 7.0 58.75 ± 3.4 72 ± 9.3 0.05
Sample retrieval method
Biopsy 5 (71%) 5 (31%) – – –
TUR-P 2 (29%) 5 (31%) 4 (100%) 6 (100%)
Radical Prostatectomy – 6 (38%) – –
Gleason Score 0.76
< 7 – 4 (25%) – 1 (17%)
8–10 – 12 (75%) 4 (100%) 5 (83%)
T Staginga 0.91
1 – 6 (37%) – –
2 – 4 (25%) 2 (50%) 3 (50%)
3 – 3 (19%) – 1 (17%)
4 – 3 (19%) 2 (50%) 2 (33%)
Lymphatic Involvements – 1 (7%) NE NE –
PSAa 9.5 (1.4–36.7) 49.3 (4.6–600) 24.13 (10.1–303.2) 203.2 (10.2–689) 0.01*
Prostate volumea 51.6 (28–73.6) 43.6 (13.4–80.5) 30.5 (28.6–36.68) 39.7 (27.6–94.2) 0.39
ADT Type 0.76
Orchyde – – 2 (50%) 4 (67%)
LHRH agonist + antiandrogen – – 2 (50%) 2 (33%)
ADT Treatment Duration – – 5 (3–9) 30 (15–70) –
N.E not evaluated
a PSA and prostate volume are presented in median (min-max)
b Sample retrieval method, T staging, and Lymphatic involvements are presented as percentages
c Statistical significance was measured by comparing Primary PCa, ADT-PCa ≤ 12months and > 12months using Pearson chi square for Gleason score, and ADT
Type; ANOVA for age; Kurskall Wallis test for T-stage, PSA level, and Prostate Volume
d ADT treatment duration is presented in months
* P-value < 0.05 is significant
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expression is described in Table 3. AR protein expres-
sion in the ADT-PCa group was increased by 80% com-
pared with that in the primary PCa group (p < 0.01),
showing an increasing trend in the ADT ≤12months
subgroup compared with the PCa group (p = 0.2), and
AR protein expression was significantly higher in the
ADT > 12months subgroup (100; p < 0.01) (Table 3). No
upregulation in AKR1C3 was found in either ADT-PCa
subgroup.
Associations between protein expression in the prostatic
tissue of ADT-PCa patients and clinicopathological
parameters
A further analysis of the ADT-PCa patients was per-
formed by examining the association between increased
protein expression and the clinical status of the patients
(data not shown). This part of the study focused on the
ADT-PCa subgroups. Specifically, we evaluated the ADT
≤12months subgroup (Table 4) to determine whether
the initial changes within the intraprostatic tissue were
due to ADT. Half of the patients in the ADT ≤12
months group and all of the patients in the ADT > 12
months group had upregulated AR expression.
Furthermore, one patient in the ADT ≤12 months sub-
group had shown AR upregulation only 3 months after
beginning ADT. However, there was no case of upregu-
lation of AKR1C3 expression in the ADT ≤12months
subgroup. Additionally, there was no notable finding for
SRD5A1, SRD5A2, and SRD5A3 protein expression.
Moreover, there were no notable significant differences
in the clinical or pathological parameters between the
patients with upregulated and nonupregulated AR within
the ADT ≤12months subgroup.
Among the patients in the group given ADT for ≤12
months, one sample had increased protein expression of
AR only, one sample had increased protein expression of
SRDA1, 2, and 3 proteins, one sample increased protein
expression of AR, SRDA1 and SRDA2, and one had no in-
crease in protein expression. The specific H-scores for
protein expression are available in Supplementary Table 2.
Discussion
Although chemical castration by ADT has been the
standard frontline therapy for advanced-stage PCa, dis-
ease progression is predicted to occur when cancer de-
velops into CRPC. To better understand the changes
Fig. 1 Gene expression analysis. Analysis of the relative expression of five different genes was performed by quantification of real-time one-step
RT-PCR using the Mx3000P (Agilent) tool in tissue samples of the BPH group (n = 12), primary PCa group (n = 13), ADT ≤12 months group (n = 4)
and ADT > 12months group (n = 6). The included AR (a), AKR1C3 (b), SRD5A1 (c), SRD5A2 (d), and SRD5A3 (e). Statistical analysis was performed
by using the Mann-Whitney test, comparing each group to another in a paired manner. * p < 0.05 and ** p < 0.01. Standard errors of the means
are indicated by bars. a-e All experiments were performed at least two times
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involved in the transition to the progressive state, thor-
ough study of the mechanisms of ADT resistance is im-
portant. The upregulation of components of the AR
signaling pathway in intraprostatic tissue is one of the
resistance mechanisms in CRPC. This study found
upregulation of AR and steroidogenic enzymes in ADT-
treated PCa patients. Furthermore, this study, in accord-
ance with other studies, found that CRPC can develop in
less than 12 months after the commencement of ADT
[19] However, until now, no study has evaluated when
the mechanism that triggers resistance to ADT becomes
active in the prostate during ADT.
This study delves into the early response to ADT by
evaluating intraprostatic AR and steroidogenic enzyme
changes using prostate tissue from patients who still ex-
perienced urinary retention during ADT. It revealed a
notably unique finding in the subgroup of patients who
had ADT for only 12 months or less. Two patients had
high intratumoral AR gene and protein expression after
3 months of ADT. It can be speculated that the resist-
ance mechanism to ADT [10] through upregulation of
AR might start as early as 3 months after the beginning
of ADT. To the best of our knowledge, this is the first
study to show early AR upregulation in human PCa












≤ 12months (n = 4) > 12 months (n = 6)
n % n % Compared to primary PCab n % Compared to primary PCab
AR 57% 1 14 2 50 0.2 6 100 < 0.01*
AKR1C3 39% 2 29 0 0 0.23 1 17 0.61
SRD5A1 41% 5 71 2 50 0.47 4 67 0.85
SRD5A2 85% 3 43 2 50 0.81 3 50 0.79
SRD5A3 41% 7 100 1 25 < 0.01* 3 50 0.03*
a H-Score cut-off was measured from mean H-score of BPH group (n = 6) as mentioned in the method, to determine upregulation of protein expressions in
malignant tissues (Primary PCa and ADT ≤ 12 months and > 12months)
b Statistical significance was measured for p-value by comparing the H score of ADT ≤ 12 months and > 12months with Primary PCa using Pearson Chi Square
* P-value < 0.05 is significant
Fig. 2 Immunohistochemistry of prostate cancer tissue stained for AR, AKR1C3, SRD5A1, SRD5A2, and SRD5A3. Comparison between the protein
expression of AR and intraprostatic steroidogenic enzymes in the prostatic cells of the primary PCa and ADT-PCa groups: a AR, b AKR1C3, c
SRD5A1, d SRD5A2, and e SRD5A3. Images were taken of sliced FFPE samples of patients obtained between 2009 and 2014 in RSCM. Images
were captured at 400.000× magnification
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tissue during ADT. This early resistance mechanism
should be a warning to clinicians that this process
should be monitored when starting ADT [20].
Another interesting result is that AR was the only
gene that was upregulated at the early stage (3
months). PCa cells might start to overcome low
serum androgen levels due to ADT by increasing AR
expression first [10–13]. This suggests that the early
mechanism to overcome low serum androgen levels is
increased AR expression [10–13]. Many in vitro stud-
ies have shown upregulation of AR expression, dem-
onstrating the adaptations of prostatic cells that
increase sensitivity to low androgen levels after treat-
ment with ADT [21–23]. However, these phenomena
can be seen only in patients with orchiectomy who
receive ADT. This might show that an abrupt de-
crease in serum testosterone levels induces the upreg-
ulation of AR. Furthermore, there are many known
mechanisms of AR changes, including gene amplifica-
tion and mutation, which have also been reported in
patients with ADT > 12 months [8–10]. However, this
study examined only protein expression and did not
further evaluate the other AR changes, namely, AR
amplification and AR mutation.
PCa cell growth is promoted by androgens, espe-
cially DHT [12]. This study found that 5α-reductase
isoenzymes, which regulate the conversion of T to
DHT [11, 12], were increased in ADT-treated PCa
patients. Similar to other studies, SRD5A1 [14, 24]
and SRD5A3 [14, 25] were upregulated in ADT-PCa
patients compared with ADT-naïve PCa patients, and
SRD5A2 was downregulated [14, 24, 26]. However,
until now, there has been very limited information on
whether the isozyme is involved in the process of an-
drogen biosynthesis. Interestingly, this study found
that SRD5A was the only steroidogenic enzyme that
was upregulated in the ADT ≤12 months group. This
SRD5A upregulation was also related to AR upregula-
tion. This suggests that PCa cells upregulate the ex-
pression of SRD5A, which is the primary enzyme
responsible for the conversion of T to DHT expres-
sion, after or at the same time as AR expression is
Table 4 ADT-treated prostate cancer patients characteristics and clinical and pathological parameters
Characteristics AR SRD5A1 SRD5A2 SRD5A3


















Age 59.5 ± 0.7 58 ± 5.6 0.75 56.5 ± 3.5 61 ± 1.4 1 56.5 ± 3.5 61 ± 1.4 1 54 60.3 ± 1.5 0.07
T Stages 0.05 0.32 0.32 0.25
1 – –
– – – – – –
2 100% – 50% 50% 50% 50%% – 67%
3 – – – – – – – –
4 – 100% 50% 50% 50% 50% 100% 33%
Gleason scorea 0.25 0.25 0.25 0.50
< 7 50% – – 50% – 50% – 33%























ADT Type – – – –
Orchyde 2 – 1 1 1 1 – 1
LHRH agonist +
antiandrogen
– 2 1 1 1 1 1 2
ADT Treatment
Duration
5 (3–7) 6 (3–9) – 8 (7–9) 3 – 8 (7–9) 3 – 9 3 (3–7) –
+ is upregulated protein expression group; − is downregulated protein expression group
a Age is presented in mean ± SD; PSA level and prostate volume are presented in median (min-max)
b Statistical significance was measured by comparing the clinical parameters of upregulated and non-upregulated ADT-PCa samples using Independent T test for
Age; Pearson chi square test for Gleason score; Mann-Whitney test for T-stages and PSA level
* P-value < 0.05 is significant
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upregulated [14]. Thus, developing a new strategy or
compound that targets SRD5A can reduce the risk of
early resistance.
Among the PCa-ADT patients with ADT durations of
less than 12months, three patients showed upregulation
of genes with increased protein expression. Three of four
patients showed upregulation of AR, with one patient
showing upregulation AR and SRD5A1, 2, and 3; one
showing upregulation of AR, SRD5A1 and SRD5A2; and
one showing only AR upregulation. These findings are
novel, as no one has ever investigated below the cut-off of
12months. This study suggests the possible upregulation
of AR and steroidogenesis enzymes (namely, SRD5A1,
SRD5A2, and SRD5A3) as a compensatory mechanism for
the low testosterone level due to ADT [14]. Our study
showed that patients whose SRD5A1, 2, or 3 level be-
comes upregulated have increased expression of the pro-
teins later (at 7–9months of ADT) than those with
upregulated AR (at 3–7months of ADT). This suggests
that the increase in AR is the first compensatory mechan-
ism, followed by the increases SRD5A1, 2, and 3. How-
ever, further studies with more patients are needed to
validate this compensatory response.
Many studies have shown that there is a shift to ad-
renal androgen usage for maintaining DHT levels via up-
regulation of AKR1C3 expression [10–14]. This study
showed that AKR1C3 can only be found in patients
treated with ADT for more than 12months, which is in
accordance with other studies [27]. The next question is
why AKR1C3 is not upregulated in the early state. Based
on the steroidogenic pathway, AKR1C3 is an upstream
enzyme that converts adrenal androgen to downstream
androgens, which are needed as a source of DHT [12–
14]. To support the previous statement, we hypothesize
that in PCa cells, AKR1C3 expression is increased after
AR and SRD5A upregulation. However, it has been
shown that there are many variations in AKR1C3,
SRD5A and AR expression among patients in the ADT
> 12months group. This might be due to the dynamic
process of steroidogenesis. The AR or steroidogenesis
enzymes are regulated based on ‘real-time’ conditions as
needed by PCa cells.
The main limitation of our study is the small sample
size. However, this is the first study that tried to evaluate
AR signaling pathway changes during ADT in human
prostate tissues. This study also revealed an important
finding in which PCa cells may adapt to low androgen
levels caused by ADT before PSA levels rise. This find-
ing is not the first significant one with interesting infor-
mation that is limited by a low sample size. One study
performed by Alsinnawi M et al. contributed significant
prognostic information in which high expression of the
SLCO gene may result in worse disease-free survival
(DFS), with only 11 samples included in the study [28].
Although the sample size was small, the results of the
mentioned study were in concordance with the results
of Terakawa T et al.’s team, who examine similar out-
comes but with more patients included (n = 494) [29].
Similar studies had similarly small sample sizes yet
showed significance in practice. With only a few sam-
ples, Tiwari et al. showed that AR and its transcriptional
corepressor REST modulate SPINK1 expression and that
SPINK1 plays a plausible role in the progression of neu-
roendocrine prostate cancer [30]. Another study by
Cheung et al., using only 11 samples per group, found
that Actin alpha cardiac muscle 1 (ACTC1) gene expres-
sion plays a role in compensating ADT administration
for PCa as a response to ADT-induced muscle loss [31].
In addition to the sample size, other limitations of our
study include the limited number samples available due
to some nonutilizable old specimens unsuitable for RNA
extraction and protein expression evaluation. Another
limitation of this study is its use of the median expres-
sion level of each gene in BPH tissues as the cut-off for
defining upregulation in other samples. This was the
only available method, as there is currently no official
validated cut-off to define upregulation of AR or ste-
roidogenic genes in immunohistochemistry staining.
In conclusion, AR and steroidogenic enzymes are up-
regulated in PCa patients who are treated with ADT.
Early AR and SRD5A upregulation can be found at 3
months in ADT patients. This indicates that the early
evaluation of AR and SRD5A expression in intraprostatic
tissue should be done. Further strategic treatment
should target AR and the SRD5A enzyme to overcome
early resistance to ADT.
Conclusion
AR and steroidogenic enzymes are upregulated in ADT-
PCa patients as early as 3 months without PSA elevation.
Steroidogenic enzymes, especially SRD5A3 expression,
were also upregulated before PSA rose.
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